EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Quanduzhong capsules for the treatment of grade 1 hypertension patients with low-to-moderate risk: A multicenter, randomized, double-blind, placebo-controlled clinical trial

Xuan Xu, Wende Tian, Wenhui Duan, Chaoxin Pan, Mingjian Huang, Qinggao Wang, Qinghua Yang, Zhihao Wen, Yu Tang, Yao Xiong, Zhiyun Zhu, Yuanyuan Liu und 10 weitere

Frontiers in Pharmacology · 10.01.2023 · 13

DOI: 10.3389/fphar.2022.1014410 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 10.01.2023. Verfasst von Xuan Xu und 21 weiteren Autor:innen. Beteiligte Einrichtung: Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Duzhong [DZ ( Eucommia ulmoides Oliv.)] is regarded as a traditional Chinese medicine with a history dating back more than 2000 years. This herb is considered a nourishing herb in China and is commonly used as a tonic to strengthen muscles and bones, nourish the kidneys and liver, and soothe miscarriages. Moreover, there is evidence that DZ is capable of regulating blood pressure (BP), and several compounds isolated from DZ have been shown to have a BP-lowering effect. Quanduzhong capsules contain an extract of DZ [ Eucommia ulmoides Oliv. (Eucommiaceae; Eucommiae cortex)] that is effective in treating hypertension. This multicenter, randomized, double-blind, placebo-controlled clinical trial sought to evaluate the clinical efficacy of Quanduzhong capsules in the treatment of low-to-moderate risk grade 1 hypertension patients. Materials and methods: A total of 60 patients from 3 centers with documented low-to-moderate risk grade 1 hypertension were randomly assigned in a 1:1 ratio to the test group or the control group. After a 1 week lead-in period using sham Quanduzhong capsules, all patients who met the entry criteria (29 cases in the test group and 29 cases in the control group) entered the 4 week test period. The test group took Quanduzhong capsules, and the control group continued to take sham Quanduzhong capsules. The primary endpoints [24-h mean systolic blood pressure (SBP) and diastolic blood pressure (DBP) determined via 24-h ambulatory blood pressure monitoring (ABPM); office SBP and DBP] and secondary endpoints [mean arterial pressure; mean pulse; daytime mean SBP and DBP; nocturnal mean SBP and DBP; SBP and DBP load; area under the blood pressure (BP) curve; morning peak BP; early morning SBP and DBP; smoothness index of SBP and DBP; 24 h BP mean coefficient of variation (CV); percentage of patients with circadian restoration in ABPM; home BP; quality of life evaluated by WHO Quality of Life-BREF questionnaire; grading and quantitative evaluation of hypertension symptoms; values of plasmatic renin activity, angiotensin II, aldosterone, β-2 microglobulin and homocysteine] were assessed following the treatment. Drug-related adverse events and adverse drug reactions were also compared.

Results

After a 4 week test period, a significant difference in the DBP CV between the two groups was observed (−2.49 ± 4.32 vs. 0.76 ± 4.3; p < .05). Moreover, the mean office SBP change was −7.62 ± 9.32 mmHg, and the mean DBP change was −4.66 ± 6.03 ( p < .05). Among the three subjects with abnormal homocysteine levels in the test group, homocysteine levels decreased by 6.23 ± 9.15 μmol/L after treatment. No differences were observed between the two groups in any other indicators. After 4 weeks of treatment, there were no significant differences between the groups in terms of safety indicators ( p > .05). No abnormal vital signs (except BP) or severe liver or renal function impairment were observed during the treatment periods; in addition, adverse events and drug reactions were mild.

Conclusion

Treatment with Quanduzhong capsules reduced office SBP and DBP as well as DBP CV determined by 24-h ambulatory BP monitoring in patients with grade 1 hypertension at low-to-moderate risk. Clinical Trial Registration: https://www.chictr.org.cn/showproj.aspx?proj=32531 , identifier ChiCTR1900021699.

Schlagwörter

Stichwörter der Autor:innen

grade 1 hypertensionlow-to-moderate riskquanduzhong capsulerandomized controlled trialtraditional Chinese medicine

Autor:innen und Institutionen

  • Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
  • National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
  • The Eighth Hospital of Baotou, Baotou, China.
  • Graduate School, China Academy of Chinese Medical Sciences, Beijing, China.
  • The First Affiliated Hospital of Guangxi University of Chinese Medicine, Guangxi, China.
  • Jiangxi Provincial People's Hospital, Nanchang, Jiangxi Province, China.

Zitieren

APA

Xu, X., Tian, W., Duan, W., Pan, C., Huang, M., Wang, Q., Yang, Q., Wen, Z., Tang, Y., Xiong, Y., Zhu, Z., Liu, Y., Wei, D., Qi, W., Ouyang, X., Ying, S., Wang, X., Zhou, Z., Li, X., …, & Xu, H. (2023). Quanduzhong capsules for the treatment of grade 1 hypertension patients with low-to-moderate risk: A multicenter, randomized, double-blind, placebo-controlled clinical trial. Frontiers in Pharmacology, 13. https://doi.org/10.3389/fphar.2022.1014410

Vancouver

Xu X, Tian W, Duan W, Pan C, Huang M, Wang Q, et al. Quanduzhong capsules for the treatment of grade 1 hypertension patients with low-to-moderate risk: A multicenter, randomized, double-blind, placebo-controlled clinical trial. Frontiers in Pharmacology. 2023;13. doi:10.3389/fphar.2022.1014410

BibTeX
@article{Xu2023,
  author = {Xu, Xuan and Tian, Wende and Duan, Wenhui and Pan, Chaoxin and Huang, Mingjian and Wang, Qinggao and Yang, Qinghua and Wen, Zhihao and Tang, Yu and Xiong, Yao and Zhu, Zhiyun and Liu, Yuanyuan and Wei, Dan and Qi, Wenqiang and Ouyang, Xiaochao and Ying, Shaozhen and Wang, Xiaohua and Zhou, Zhigang and Li, Xiaofeng and Cui, Yu and Yang, Shuyin and Xu, Hao},
  title = {Quanduzhong capsules for the treatment of grade 1 hypertension patients with low-to-moderate risk: A multicenter, randomized, double-blind, placebo-controlled clinical trial},
  journal = {Frontiers in Pharmacology},
  year = {2023},
  volume = {13},
  doi = {10.3389/fphar.2022.1014410}
}
Kostenlos starten →